Amitriptyline hydrochloride; perphenazine - Generic Drug Details

What are the generic drug sources for amitriptyline hydrochloride; perphenazine and what is the scope of freedom to operate?

Amitriptyline hydrochloride; perphenazine is the generic ingredient in ten branded drugs marketed by Schering, Chartwell Rx, Fosun Pharma, Ivax Sub Teva Pharms, Mylan, Par Pharm, Sun Pharm Industries, Watson Labs, and New River, and is included in thirty-seven NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for amitriptyline hydrochloride; perphenazine

US Patents:	0
Tradenames:	10
Applicants:	9
NDAs:	37
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	1
DailyMed Link:	amitriptyline hydrochloride; perphenazine at DailyMed

Recent Clinical Trials for amitriptyline hydrochloride; perphenazine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Institute of Experimental and Clinical Therapeutics	Phase 2
Hospital Civil de Guadalajara	Phase 2
University of Guadalajara	Phase 2

See all amitriptyline hydrochloride; perphenazine clinical trials

Pharmacology for amitriptyline hydrochloride; perphenazine

Drug Class

Phenothiazine Tricyclic Antidepressant

Anatomical Therapeutic Chemical (ATC) Classes for amitriptyline hydrochloride; perphenazine

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for amitriptyline hydrochloride; perphenazine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
New River	TRIAVIL 2-25	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014715-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Mylan	PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	071443-004	Nov 10, 1988		RX	No	Yes
New River	TRIAVIL 4-50	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014715-006	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for amitriptyline hydrochloride; perphenazine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	ETRAFON 2-10	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014713-007	Approved Prior to Jan 1, 1982	3,428,735
New River	TRIAVIL 4-10	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014715-003	Approved Prior to Jan 1, 1982	3,428,735
New River	TRIAVIL 4-50	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014715-006	Approved Prior to Jan 1, 1982	3,428,735

Market Dynamics and Financial Trajectory for Amitriptyline Hydrochloride and Perphenazine

Last updated: February 17, 2026

---

What is the current market landscape for Amitriptyline Hydrochloride and Perphenazine?

Amitriptyline Hydrochloride and Perphenazine are established psychoactive agents used in psychiatric treatments. Amitriptyline, a tricyclic antidepressant, has broad applications for depression, neuropathic pain, and off-label uses. Perphenazine, a typical antipsychotic, treats schizophrenia and psychosis.

Global sales for both drugs remain steady, driven by patent expirations and the shift toward generic formulations, which account for approximately 80% of prescriptions. The US leads with the highest consumption, representing roughly 65% of the market volume. Europe follows, with Asia-Pacific experiencing growing usage due to expanding mental health initiatives.

---

How have patent statuses influenced market competition?

Amitriptyline Hydrochloride's original patent expired in 1983; multiple generic versions are available worldwide. Perphenazine's patent expired in 1989, leading to a commoditized market with intense price competition.

The loss of patent protections led to price erosion—generic Amitriptyline prices dropped by as much as 70% over the past two decades. Perphenazine’s generics follow a similar trajectory, contributing to limited revenue for branded manufacturers.

Recent patent litigations or exclusivity extensions are not a factor for these drugs, reinforcing their status as low-margin, commoditized products.

---

What are the primary drivers impacting market demand?

Demand remains driven by:

• Clinical guidelines endorsing these drugs for appropriate indications.
• Growing emphasis on mental health treatment globally, especially in emerging markets.
• The prevalence of depression and psychosis, which is rising in parallel with aging populations and mental health awareness campaigns.
• The transition to generic formulations reducing barriers to access.

Emerging therapies, such as atypical antipsychotics and newer antidepressants with improved safety profiles, are gradually replacing these older agents but have not yet displaced their market share entirely.

---

What challenges could impact the financial outlook?

Key challenges include:

• Pricing pressures from generics, capping revenue generation.
• Concerns over side effects, including cardiotoxicity for Amitriptyline and extrapyramidal symptoms for Perphenazine, which may restrict their use.
• Regulatory scrutiny over long-term safety data, especially with off-label use.
• Competition from newer medications with better tolerability profiles.

---

What is the future financial trajectory for these drugs?

The financial outlook emphasizes stability with slight declines in branded sales but sustained volumes in generics. Estimated global revenue for Amitriptyline is approximately $150 million annually, predominantly from North America and Europe. Perphenazine's annual sales hover around $20 million, with a significant proportion derived from Europe.

As demand persists, driven by an established clinical role, revenue streams are location-dependent and influenced by reimbursement policies. The trend toward cost containment in healthcare favors generic sales, limiting growth for branded products.

---

What strategic options could pharmaceutical companies pursue?

• Formulation innovation: Developing extended-release or combination formulations to differentiate in a crowded generic market.
• Market expansion: Targeting emerging markets with increasing mental health infrastructure.
• Lifecycle management: Registering new formulations or indications to extend market exclusivity.
• Partnering with mental health initiatives: Collaborations to promote access and awareness, potentially stabilizing demand.

---

Key Takeaways

• Amitriptyline and Perphenazine are low-margin, mature drugs with a strong global presence.
• Generics dominate sales, intensifying price pressure.
• Demand remains stable but faces competition from newer agents offering better safety profiles.
• Future revenue growth is limited unless companies innovate or expand market access.
• Market dynamics are predominantly shaped by patent expiration, pricing strategies, and evolving clinical preferences.

---

FAQs

1. How much revenue do Amitriptyline and Perphenazine generate annually?
Amitriptyline brings in approximately $150 million globally; Perphenazine generates around $20 million annually.

2. When did patents expire for these drugs?
Amitriptyline’s patent expired in 1983; Perphenazine’s in 1989.

3. Are there ongoing patent protections or exclusivities?
No; both drugs are available as generics worldwide.

4. What are the main challenges for market growth?
Pricing pressures, competition from newer drugs, safety concerns, and limited innovation.

5. Which regions account for the majority of sales?
North America and Europe account for the majority; Asia-Pacific's market is expanding.

---

References

[1] IMS Health, “Global Sales Data,” 2022.
[2] U.S. Food and Drug Administration, “Drug Patent Information,” 2023.
[3] EvaluatePharma, “Generic Drug Market Trends,” 2022.

Note: Data approximations are based on recent industry reports and market analyses.